3-Dimensional, Wyeth-Ayerst deal

The companies will develop 3-Dimensional's orally active thrombin inhibitors for deep vein thrombosis,

Read the full 131 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE